DiaMedica's Type 2 Diabetes Antibody Shown to Increase Glucose Infusion Rate by 291%

Source :: Internet Wire. April 19, 2011
Publication Year :: 2011
Abstract: Byline: WINNIPEG, MANITOBA, Apr 19, 2011 (MARKETWIRE via COMTEX) -- DiaMedica (TSX VENTURE: DMA) today announces positive and important activity with DM-204, its lead monoclonal antibody. In a gold-standard animal [...]

Subjects :: Diabetes therapy -- Physiological aspects
Biological products -- Physiological aspects
Blood sugar -- Physiological aspects
Glucose metabolism -- Physiological aspects
Antihypertensive drugs -- Dosage and administration -- Physiological aspects
Diabetics -- Physiological aspects
Type 2 diabetes -- Physiological aspects
Monoclonal antibodies -- Dosage and administration -- Physiological aspects
Medical screening -- Physiological aspects
Hypertension -- Physiological aspects
Business
Business, international
News, opinion and commentary

Tools